Novavax, Inc.
NVAX · NASDAQ
Company research
Novavax, Inc. (NASDAQ: NVAX) is a Gaithersburg, Maryland-based biotechnology company founded in 1987 that specializes in the discovery, development, and commercialization of protein-based vaccines for serious infectious diseases. The company's proprietary technology platform combines recombinant nanoparticle technology with its patented Matrix-M™ adjuvant, which enhances immune responses by stimulating both antibody production and cellular immunity without the use of live viruses. Novavax's lead commercial product is its COVID-19 vaccine (NVX-CoV2373), marketed under the brand names Nuvaxovid and Covovax, which has received regulatory authorization in over 40 countries, and the company is also advancing a COVID-19-Influenza Combination (CIC) vaccine candidate as well as supporting the R21/Matrix-M malaria vaccine. Under CEO John C. Jacobs, Novavax has pivoted its growth strategy toward out-licensing its technology platform and vaccine assets through strategic partnerships with global collaborators such as Sanofi, Takeda, and the Serum Institute of India, generating revenue through upfront licensing fees, development milestones, and long-term royalties.
Research reports
Analyzes Novavax’s transition to a lean, partnership-led Matrix‑M platform, highlighting improved cost structure but significant uncertainty around revenue visibility, execution, and pipeline durability.
BioEquity Watch (Substack) · April 2, 2026DD: Novovax ($NVAX)Argues Novavax is mispriced, describing an asset‑light licensing/IP platform built on Sanofi and Pfizer deals, with CIC Phase 3 as the central re‑rating catalyst and a $22 upside target.
Zacks Investment Research · January 10, 2026Novavax, Inc. (NVAX) – Zacks Equity Research ReportMaintains a neutral rating and $7.50 6–12‑month target, emphasizing the Sanofi partnership, vaccine pipeline progress, aggressive cost‑reduction plans, and solid cash runway while warning that regulatory and commercial setbacks could restrain performance.
Flash (StockSentinel.ai) · January 4, 2026Novavax, Inc. (NVAX) Stock Research ReportPositions Novavax as a mispriced, cash‑backed royalty platform leveraging the Sanofi deal and CIC program, with detailed scenario analysis highlighting asymmetric upside if royalty streams ramp and Phase 3 data are successful.